Kodiak Sciences (KOD) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Market opportunity and unmet needs

• Retinal vascular diseases affect 10–15 million patients in the US, with global branded biologics sales at $14B and projected to reach $18B by 2028, driven by aging and diabetes prevalence.

• Current anti-VEGF agents offer only modest vision gains and require frequent injections, with durability remaining a key unmet need; newer agents like faricimab provide only incremental improvements.

• Diabetic retinopathy is under-treated due to treatment burden, with only 1% of US patients receiving anti-VEGF therapy.

• There is a significant unmet need for therapies with improved durability and efficacy, especially for diabetic retinopathy and inflammatory retinal diseases.

Pipeline and product strategy

• Three late-stage programs: tarcocimab (anti-VEGF), KSI-501 (dual IL-6/VEGF inhibitor), and KSI-101 (dual IL-6/VEGF protein for inflammation), each with distinct mechanisms and market opportunities.

• Tarcocimab and KSI-501 are designed as mainstay biologics with high efficacy and up to six-month dosing flexibility, incorporating enhanced formulations with unconjugated protein for improved immediacy and durability.

• KSI-101 targets a greenfield market in retinal inflammatory conditions, with potential expansion into broader macular edema indications.

• Kodiak owns full commercial rights and has invested in large-scale manufacturing, including a cGMP facility in Switzerland, and home monitoring technology.

Clinical development and milestones

• Eight pivotal studies underway, with over 2,500 patient-years of experience and nearly 14,000 injections administered.

• Tarcocimab in phase III GLOW2 (diabetic retinopathy) and Daybreak (wet AMD) studies, both nearing full enrollment; top-line data expected in 2026.

• KSI-501 is in phase III for wet AMD, aiming for fast-follow registration after tarcocimab, with pivotal data readouts expected in 1H26.

• KSI-101 phase Ib Apex study in macular edema secondary to inflammation (MESI) shows strong early efficacy and safety across all dose levels, with pivotal program initiation planned for 2Q25 and pediatric studies under consideration.

• Enhanced formulations are expected to resolve prior immediacy issues, and all ABC medicines will incorporate these improvements going forward.